vs
Gitlab Inc.（GTLB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Gitlab Inc.的季度营收约是Orthofix Medical Inc.的1.1倍（$244.4M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -3.4%，领先2.4%），Gitlab Inc.同比增速更快（24.6% vs 2.0%），Gitlab Inc.自由现金流更多（$28.4M vs $16.8M），过去两年Gitlab Inc.的营收复合增速更高（22.1% vs 8.0%）
GitLab Inc.是一家美国企业，开发并运营同名开放核心架构DevOps软件平台，覆盖软件开发、安全防护、运维运营全流程。产品基于Git分布式版本控制技术搭建，还为各项目提供访问控制、缺陷追踪、需求管理、任务调度、项目知识库、代码片段分享等全栈协作功能。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GTLB vs OFIX — 直观对比
营收规模更大
GTLB
是对方的1.1倍
$219.9M
营收增速更快
GTLB
高出22.7%
2.0%
净利率更高
OFIX
高出2.4%
-3.4%
自由现金流更多
GTLB
多$11.6M
$16.8M
两年增速更快
GTLB
近两年复合增速
8.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $244.4M | $219.9M |
| 净利润 | $-8.3M | $-2.2M |
| 毛利率 | 86.8% | 71.1% |
| 营业利润率 | -5.1% | 0.2% |
| 净利率 | -3.4% | -1.0% |
| 营收同比 | 24.6% | 2.0% |
| 净利润同比 | -128.0% | 92.4% |
| 每股收益（稀释后） | $-0.05 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTLBOFIX
| Q4 25 | $244.4M | $219.9M | ||
| Q3 25 | $236.0M | $205.6M | ||
| Q2 25 | $214.5M | $203.1M | ||
| Q1 25 | $211.4M | $193.6M | ||
| Q4 24 | $196.0M | $215.7M | ||
| Q3 24 | $182.6M | $196.6M | ||
| Q2 24 | $169.2M | $198.6M | ||
| Q1 24 | $163.8M | $188.6M |
净利润GTLBOFIX
| Q4 25 | $-8.3M | $-2.2M | ||
| Q3 25 | $-9.2M | $-22.8M | ||
| Q2 25 | $-35.9M | $-14.1M | ||
| Q1 25 | $5.8M | $-53.1M | ||
| Q4 24 | $29.6M | $-29.1M | ||
| Q3 24 | $12.9M | $-27.4M | ||
| Q2 24 | $-54.6M | $-33.4M | ||
| Q1 24 | $-36.5M | $-36.0M |
毛利率GTLBOFIX
| Q4 25 | 86.8% | 71.1% | ||
| Q3 25 | 87.9% | 72.2% | ||
| Q2 25 | 88.3% | 68.7% | ||
| Q1 25 | 89.2% | 62.8% | ||
| Q4 24 | 88.7% | 69.0% | ||
| Q3 24 | 88.3% | 68.7% | ||
| Q2 24 | 88.9% | 67.8% | ||
| Q1 24 | 90.2% | 67.5% |
营业利润率GTLBOFIX
| Q4 25 | -5.1% | 0.2% | ||
| Q3 25 | -7.8% | -8.3% | ||
| Q2 25 | -16.1% | -7.9% | ||
| Q1 25 | -9.1% | -25.2% | ||
| Q4 24 | -14.7% | -5.3% | ||
| Q3 24 | -22.5% | -9.6% | ||
| Q2 24 | -31.7% | -12.5% | ||
| Q1 24 | -21.3% | -15.6% |
净利率GTLBOFIX
| Q4 25 | -3.4% | -1.0% | ||
| Q3 25 | -3.9% | -11.1% | ||
| Q2 25 | -16.7% | -6.9% | ||
| Q1 25 | 2.7% | -27.4% | ||
| Q4 24 | 15.1% | -13.5% | ||
| Q3 24 | 7.1% | -13.9% | ||
| Q2 24 | -32.3% | -16.8% | ||
| Q1 24 | -22.3% | -19.1% |
每股收益（稀释后）GTLBOFIX
| Q4 25 | $-0.05 | $-0.05 | ||
| Q3 25 | $-0.06 | $-0.57 | ||
| Q2 25 | $-0.22 | $-0.36 | ||
| Q1 25 | $0.05 | $-1.35 | ||
| Q4 24 | $0.18 | $-0.76 | ||
| Q3 24 | $0.08 | $-0.71 | ||
| Q2 24 | $-0.35 | $-0.88 | ||
| Q1 24 | $-0.23 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $224.2M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $922.7M | $450.0M |
| 总资产 | $1.6B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GTLBOFIX
| Q4 25 | $224.2M | $82.0M | ||
| Q3 25 | $261.4M | $62.9M | ||
| Q2 25 | $255.7M | $65.6M | ||
| Q1 25 | $227.6M | $58.0M | ||
| Q4 24 | $176.6M | $83.2M | ||
| Q3 24 | $438.6M | $30.1M | ||
| Q2 24 | $420.3M | $26.4M | ||
| Q1 24 | $288.0M | $27.0M |
总债务GTLBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益GTLBOFIX
| Q4 25 | $922.7M | $450.0M | ||
| Q3 25 | $866.6M | $442.5M | ||
| Q2 25 | $808.3M | $458.3M | ||
| Q1 25 | $775.9M | $458.3M | ||
| Q4 24 | $724.7M | $503.1M | ||
| Q3 24 | $642.8M | $525.9M | ||
| Q2 24 | $567.8M | $546.0M | ||
| Q1 24 | $571.2M | $570.3M |
总资产GTLBOFIX
| Q4 25 | $1.6B | $850.6M | ||
| Q3 25 | $1.5B | $832.6M | ||
| Q2 25 | $1.4B | $837.2M | ||
| Q1 25 | $1.4B | $823.1M | ||
| Q4 24 | $1.3B | $893.3M | ||
| Q3 24 | $1.4B | $867.9M | ||
| Q2 24 | $1.3B | $882.0M | ||
| Q1 24 | $1.3B | $906.0M |
负债/权益比GTLBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $28.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 11.6% | 7.6% |
| 资本支出强度资本支出/营收 | 1.2% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $242.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流GTLBOFIX
| Q4 25 | $31.4M | $27.7M | ||
| Q3 25 | $49.4M | $12.4M | ||
| Q2 25 | $106.3M | $11.6M | ||
| Q1 25 | $63.2M | $-18.4M | ||
| Q4 24 | $-177.0M | $23.7M | ||
| Q3 24 | $11.7M | $11.7M | ||
| Q2 24 | $38.1M | $9.0M | ||
| Q1 24 | $24.9M | $-18.6M |
自由现金流GTLBOFIX
| Q4 25 | $28.4M | $16.8M | ||
| Q3 25 | $46.5M | $2.5M | ||
| Q2 25 | $105.4M | $4.5M | ||
| Q1 25 | $62.1M | $-25.1M | ||
| Q4 24 | $-178.1M | $15.2M | ||
| Q3 24 | $10.8M | $6.3M | ||
| Q2 24 | $37.4M | $-360.0K | ||
| Q1 24 | $24.5M | $-29.1M |
自由现金流率GTLBOFIX
| Q4 25 | 11.6% | 7.6% | ||
| Q3 25 | 19.7% | 1.2% | ||
| Q2 25 | 49.1% | 2.2% | ||
| Q1 25 | 29.4% | -13.0% | ||
| Q4 24 | -90.8% | 7.0% | ||
| Q3 24 | 5.9% | 3.2% | ||
| Q2 24 | 22.1% | -0.2% | ||
| Q1 24 | 15.0% | -15.4% |
资本支出强度GTLBOFIX
| Q4 25 | 1.2% | 4.9% | ||
| Q3 25 | 1.2% | 4.8% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 0.5% | 3.5% | ||
| Q4 24 | 0.5% | 4.0% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.4% | 4.7% | ||
| Q1 24 | 0.2% | 5.6% |
现金转化率GTLBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 10.89× | — | ||
| Q4 24 | -5.99× | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTLB
| Subscription And Circulation | $146.4M | 60% |
| Subscription Software As A Service | $76.9M | 31% |
| License | $15.5M | 6% |
| Professional Services And Other | $5.6M | 2% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
